


Half Yearly Report 2012



Our Mission

To improve the quality of human life by providing innovative pharmaceutical products through continuous research and development ensuring stakeholders satisfaction.

Our Vision

To be regarded and recognized as one of the most value -driven Pharmaceuticals Companies in the world.

Goals

To be the market leader.

Serve our customers with quality products at a reasonable price.

Develop our employees with high potentials and an opportunity of career development.

Establish strong regional presence.

Provide our shareholders a steady asset growth and return on investment.

Recognize the suppliers as our business partner`s and Competitors as the contributor to the market value.


Grow revenue and profit.

Our Values

- Quality in everything we do
- Live up to our commitment
- Trust & respect for each other
- Transparent & fair in all our dealings
- Take initiative to exceed standard
- Work as a team
- Share social responsibilities

Dear Shareholders

We are pleased to present the un-audited Financial Statements for the half year ended 31st December 2012 of the company containing Balance Sheet, Income Statement, Statement of Changes in Equity and Cash Flow Statement thereof.


Md. Ebadul Karim
Managing Director


BEACON PHARMACEUTICALS LTD.


153-154, Tejgaon Industrial Area, Dhaka-1208

STATEMENT OF FINANCIAL POSITION (Un-audited)

As at 31st December, 2012

Particulars[]	31-Dec-12[]	30-Jun-12
ASSETS		
Non-Current Assets:		
Property, Plant & Equipments[]	2,624,556,227[]	2,698,805,180
Deferred IPO Expense[]	16,570,506 []	18,937,721
Total Non-Current Assets[]	2,641,126,733 []	2,717,742,901
Current Assets:		
Inventories[]	899,536,188[]	997,651,472
Accounts Receivable[]	129,304,330[]	125,677,319
Advance, Deposit & Pre-payments[]	393,672,436[]	428,150,505
Cash & Cash Equivalents[]	30,469,908[]	7,202,584
Total Current Assets[]	1,452,982,864[]	1,558,681,879
Investment in Shares[]	235,000,000[]	235,000,000
TOTAL ASSETS[]	4,329,109,598[]	4,511,424,780
SHAREHOLDERS' EQUITY & LIABILITIES		
Shareholders' Equity:		
Paid up Capital[]	2,310,000,000[]	2,310,000,000
Reserve and Surplus[]	345,413,923[]	354,275,787
Retained Earning[]	110,644,336[]	99,851,475
Total Shareholders' Equity[]	2,766,058,259[]	2,764,127,262
Non-Current Liabilities:		
Long Term Loan[]	782,818,741[]	850,076,683
Current Liabilities:		
Liabilities for EWF & WPPF[]	14,136,328[]	13,811,090
Short Term Loan[]	548,576,287[]	623,092,288
Current Portion of Long Term Loan[]	106,148,124[]	150,567,892
Share Application Money Refundable[]	4,879,622[]	5,180,995
Accounts Payable[]	13,653,293[]	21,020,482
Tax & VAT Payable[]	62,534,282[]	63,994,738
Accrued Expense[]	30,304,662[]	19,553,351
Total Current Liabilities[]	780,232,598[]	897,220,835
TOTAL SHAREHOLDERS' EQUITY & LIABILITIES[]	4,329,109,598[]	4,511,424,780
Net Asset value (NAV) / Share[]	11.97[]	11.97
Par Value(Tk.)[]	10.00[]	10.00


Company Secretary


Managing Director


BEACON PHARMACEUTICALS LTD.


153-154, Tejgaon Industrial Area, Dhaka-1208

STATEMENT OF COMPREHENSIVE INCOME (Un-Audited)

For the half year ended 31st December, 2012

Particulars[]	July to Dec'12[] Half Yearly[]	July to Dec'11[] Half Yearly[]	Oct to Dec'12[] 2nd Quarter[]	Oct to Dec'11 2nd Quarter[]
Turnover (Net of VAT)[]	564,713,500[]	477,866,285[]	298,602,668[]	240,416,220
Less: Cost of Goods Sold[]	269,650,696[]	221,465,265[]	140,880,596[]	117,296,489
Gross Profit[]	295,062,804[]	256,401,020[]	157,722,072[]	123,119,731
Less: Administrative Expense[]	32,800,102[]	17,743,817[]	16,676,840[]	9,117,770
Less: Marketing, Selling & Distribution Exp.[]	168,002,266 []	71,830,284[]	105,519,443[]	37,025,126
Total Operating Expense[]	200,802,369[]	89,574,101[]	122,196,284[]	46,142,896
Operating Profit[]	94,260,435[]	166,826,919[]	35,525,788[]	76,976,835
Less: Financial Expense[]	91,474,420[]	104,620,210[]	41,592,143[]	51,468,650
Net Profit after Financial Expense[]	2,786,015[]	62,206,709[]	(6,066,355)[]	25,508,185
Income from other sources[]	2,825,274[]	1,070,453[]	2,090,250[]	137,295
Net Profit before IPO Expense[]	5,611,290[]	63,277,162[]	(3,976,104)[]	25,645,480
Less: Deferred IPO Expense[]	2,367,215[]	2,367,215[]	1,183,607[]	1,183,608
Net Profit before contribution to WPPF[]	3,244,075[]	60,909,947[]	(5,159,711)[]	24,461,872
Less: Contribution to WPPF[]	154,480[]	2,900,474[]	(245,701)[]	1,164,851
Net Profit before tax[]	3,089,595[]	58,009,473[]	(4,914,011)[]	23,297,021
Less: Income tax[]	1,158,598[]	17,959,202[]	(1,842,754)[]	7,014,487
Profit after tax[]	1,930,997[]	40,050,271[]	(3,071,257)[]	16,282,534
No of Shares []	231,000,000[]	231,000,000[]	231,000,000[]	231,000,000
Earning Per Share[]	0.01[]	0.17[]	(0.01)[]	0.07


Company Secretary


Managing Director


BEACON PHARMACEUTICALS LTD.


153-154, Tejgaon Industrial Area, Dhaka-1208

STATEMENT OF CASH FLOW (Un-audited)

For the half year ended 31st December, 2012

Particulars[]	31-Dec-12[]	31-Dec-11
Cash Flows from Operating Activities:		
Collection against Sales[]	546,029,045[]	459,400,009
Payment to Creditors []	(118,953,555)[]	(215,233,905)
Other Operating Expense[]	(158,593,526)[]	(101,500,086)
Interest Paid[]	(91,474,420)[]	(20,000)
Received from other sources []	2,825,274[]	-
Net Cash Generated from Operating Activities []	179,832,819[]	142,646,018
Cash Flows from Investing Activities		
Acquisition of Property, Plant & Equipments[]	(14,490,178)[]	(15,202,851)
Investment in Shares[]	-[]	-
Interest and Other Received[]	-[]	1,070,453
Payment to others[]	-[]	(11,842,395)
Net Cash Generated from Investing Activities[]	(14,490,178)[]	(25,974,793)
Cash Flows from Financing Activities		
Capital Received[]	-[]	-
Deferred IPO Expense[]	-[]	-
Excess Share Application Money Received[]	-[]	-
Excess Share Application Money Refund[]	(301,373)[]	(488,740)
Long Term Loan Received[]	-[]	-
Long Term Loan Refund[]	(67,257,942)[]	(109,018,764)
Short Term Loan Received[]	-[]	-
Short Term Loan Refund []	(74,516,001)[]	-
Net Cash Generated from Financing Activities[]	(142,075,316)[]	(109,507,504)
Total Cash Flow[]	23,267,325[]	7,163,721
Cash and Cash Equivalent - Opening []	7,202,584[]	21,563,976
Cash and Cash Equivalent - Closing[]	30,469,908[]	28,727,697
Operating Cash flow per Share[]	0.78[]	0.62
Nos. of Shares Issued[]	231,000,000[]	231,000,000


Company Secretary


Managing Director

STATEMENT OF CHANGES IN EQUITY (Un-Audited)


For the half year ended 31st December, 2012


Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning of the year[]	2,310,000,000[]	348,772,895[]	5,503,099[]	99,851,475[]	2,764,127,262
Prior year adjustment[]	-[]	-[]	-[]	-[]	-
Net Profit (Loss) transferred from Income Statement[]	-[]	-[]	-[]	1,930,997[]	1,930,997
Revaluation Reserve adjustment[]	-[]	(8,861,864)[]	-[]	8,861,864[]	-
Transferred to Tax Holiday Reserve []	-[]	-[]	-[]	-[]	-
Investment from Tax-Holiday Reserve[]	-[]	-[]	-[]	-[]	-
Shares Issued during the year / Payment of Stock Dividend[]	-[]	-[]	-[]	-[]	-
Total []	2,310,000,000[]	339,910,924[]	5,503,099[]	110,644,336[]	2,766,058,259

STATEMENT OF CHANGES IN EQUITY (Un-Audited)

For the half year ended 31st December, 2011

Particulars	Share Capital	Revaluation Reserve	Tax holiday Reserve	Retained Earnings	Total Equity
At the beginning of the year []	2,200,000,000[]	366,496,416[]	5,503,099[]	116,866,586[]	2,688,866,101
Prior year adjustment[]	-[]	-[]	-[]	-[]	-
Net Profit (Loss) transferred from Income Statement[]	-[]	-[]	-[]	40,050,271[]	40,050,271
Revaluation Reserve adjustment[]	-[]	(8,861,864)[]	-[]	8,861,864[]	-
Transferred to Tax-Holiday Reserve[]	-[]	-[]	-[]	-[]	-
Investment from Tax-Holiday Reserve[]	-[]	-[]	-[]	-[]	-
-Shares Issued during the year[]	-[]	-[]	-[]	-[]	-
Total[]	2,200,000,000[]	357,634,552[]	5,503,099[]	165,778,721[]	2,728,916,372


Managing Director


Company Secretary

Notes to the Financial Position

For the half year ended 31st December, 2012

1.00[]Selected explanatory notes:

The financial statements have been prepared in line with accounting policies as adopted in the preparation of financial statements for the period ended 31st December, 2012. This interim financial report includes those selected explanatory notes as were deemed appropriate for the better understanding of the said un-audited financial statements.

2.00[]Presentation of financial statements and basis of accounting:

The financial statements have been prepared in accordance with Generally Accepted Accounting Principles under Historical Cost Convention and after compliance with Bangladesh Financial Reporting Standard (BFRS) & Bangladesh Accounting Standard (BASs) adopted by the Institute of Chartered Accountants of Bangladesh (ICAB), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

3.00[]Property, Plant & Equipment:

3.01[]Recognition and Measurement

Property, plant and equipment are capitalized at cost less accumulated depreciation in compliance with the requirements of BAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refunded taxes.

Fixed Assets as on 01.07.2012[] 14,490,178

Addition during the year[] 3,179,469,048

Accumulated Depreciation as on 31.12.2012[] (569,402,979)

Written Down Value as on 31.12.2012[] 2,624,556,227

4.00[]Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by BAS 2: Inventories. Cost determined on weighted average cost basis. The cost of inventories comprises of expenditure in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale

4.01[]Closing Stock

Raw Materials[] 239,870,127

Work-in-Process[] 34,875,346

Finished Goods[] 501,808,519

Packing Materials[] 64,428,178

Literature & Promotional Materials[] 16,923,994

Laboratory Chemicals[] 20,514,862

Stock of Stationery[] 4,963,873

Spares & Accessories[] 16,151,289

Balance as on 31st December, 2012[] 899,536,188

5.00[]Cash and Cash Equivalents:

Cash and Cash equivalents includes cash in hand and with banks on current and deposit accounts which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

5.01[]Cash and Cash Equivalents:

Cash in hand[] 3,273,562

Cash at Bank[] 27,196,346

□ Total Cash and Cash Equivalents:[] 30,469,908